Mustang Bio will use a newly licensed cell transduction enhancer to make MB-207, its candidate therapy for “bubble boy disease.” The US biotech licensed rights to Sirion Biotech’s Lentiboost technology last week, explaining it will apply the transduction enhancer its X-linked severe combined immunodeficiency development (XSCID) program. CEO Manuel Litchman said, “Transduction enhancers were added to the cell processing of the lentiviral gene therapy in 2019 and several advantages have been observed. He added the firm plans to file an…